This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Neurology	Suppressor of cytokine signaling 3 (SOCS3)	<p><i>In vitro</i> studies suggest the cardiovascular drug Lopid gemfibrozil could be repurposed to treat neuroinflammatory and neurodegenerative diseases. In mouse microglia or astrocytes, Lopid dose-dependently increased levels of Socs1, Socs2 and Socs3 mRNA, which protect against neuronal inflammation, compared with vehicle. Ongoing work includes testing gemfibrozil in an animal model of multiple sclerosis (MS), and next steps include testing the compound in other animal models of neurodegenerative diseases. Pfizer Inc. markets Lopid to treat hypercholesterolemia and coronary artery disease (CAD).</p> <p>SciBX 5(27); doi:10.1038/scibx.2012.708 Published online July 12, 2012</p>	Unpatented; available for licensing	<p>Ghosh, A. & Pahan, K. <i>J. Biol. Chem.</i>; published online June 8, 2012; doi:10.1074/jbc.M112.346932 Contact: Kalipada Pahan, Rush University Medical Center, Chicago, Ill. e-mail: kalipada_pahan@rush.edu</p>